TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).
Study Type
OBSERVATIONAL
Enrollment
500,000
Observational
Keck School of Medicine of USC
Los Angeles, California, United States
Stanford Medicine
Redwood City, California, United States
Georgetown Medstar Transplant Institute
Washington D.C., District of Columbia, United States
To characterize the natural history of disease in patients with CLD from various etiologies and Cirrhosis
Time frame: 20 Years
To assess safety and effectiveness of CLD/Cirrhosis treatments and treatments for complications of any chronic liver disease
Time frame: 20 Years
To establish learning health networks focused on quality of care for patients
Time frame: 20 Years
To evaluate provider management practices in the treatment of patients with CLD/Cirrhosis
Time frame: 20 Years
To evaluate longitudinal and patient reported outcomes in CLD/Cirrhosis
Time frame: 20 Years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rush University Medical Center
Chicago, Illinois, United States
Columbia University Irving Medical Center/ New York Presbyterian Hospital
New York, New York, United States
Atrium Health Center for Liver Disease and Transplant
Charlotte, North Carolina, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Temple University - Lewis Katz School of Medicine
Philadelphia, Pennsylvania, United States
Baylor Scott & White Research Institute
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States